
                                  SCHEDULE 14A


                            SCHEDULE 14A INFORMATION
                Proxy Statement Pursuant to Section 14(a) of the
                         Securities Exchange Act of 1934

Filed by the Registrant    [X]

Filed by Party other than the Registrant    [  ]

Check the appropriate box:

[ ]   Preliminary Proxy Statement
[ ]   Confidential, for Use of the Commission Only (as permitted by Rule
      14a-6(e)(2))
[X]   Definitive Proxy Statement
[ ]   Definitive Additional Materials
[ ]   Soliciting Material Pursuant to ss.240.14a-12


                              ADVANTEGO CORPORATION
              ----------------------------------------------------
                (Name of Registrant as Specified In Its Charter)

                    William T. Hart - Attorney for Registrant
              ----------------------------------------------------
                   (Name of Person(s) Filing Proxy Statement)


Payment of Filing Fee (Check the appropriate box):

[X]     No fee required.

[ ]     Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)      Title of each class of securities to which transaction applies:

---------------------------------------------------

(2)      Aggregate number of securities to which transaction applies:

---------------------------------------------------

(3) Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):

---------------------------------------------------

                                       1
<PAGE>

(4) Proposed maximum aggregate value of transaction:

---------------------------------------------------

(5) Total fee paid:

---------------------------------------------------

[ ] Fee paid previously with preliminary materials.

[ ]  Check box if any part of the fee is offset as provided by Exchange Act
     Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
     paid previously. Identify the previous filing by registration statement
     number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

---------------------------------------------------

(2)      Form, Schedule or Registration Statement No.:

---------------------------------------------------

(3)      Filing Party:

---------------------------------------------------

(4)      Date Filed:

---------------------------------------------------




                                       2
<PAGE>

                              ADVANTEGO CORPORATION
                             1 Park Plaza, Suite 600
                                Irvine, CA 92614
                                 (949) 627-8977

                    NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
                                   TO BE HELD
                                December 12, 2019

To the Stockholders:

     Notice is hereby  given  that a special  meeting of the  stockholders  (the
"Meeting")  of  Advantego  Corporation  (the  "Company")  will be held at 1 Park
Plaza,  Suite 600, Large Conference Room,  Irvine, CA 92614 on December 12, 2019
at 10:00 a.m. (Pacific Time), for the following purpose:

     o    to approve an amendment to the Company's  Articles of Incorporation to
          increase the Company's  authorized  capitalization  to  15,000,000,000
          shares of common stock.

     October 30, 2019 is the record date for the  determination  of stockholders
entitled to notice of and to vote at the Meeting (the "Record Date"). Holders of
the  Company's  common stock,  and Series B preferred  stock are entitled to one
vote per share at the special meeting of shareholders.  Holders of the Company's
Series A  preferred  stock are  entitled to 1,000 votes per share at the special
meeting of shareholders.

     Shareholders  of the  Company  owning  approximately  27% of the  Company's
outstanding  common  stock and all of the  outstanding  shares of the  Company's
Series  A  preferred  stock  (two  persons)  intend  to one vote in favor of the
proposal to come before the meeting.

                                         ADVANTEGO CORPORATION


October 30, 2019                         Robert W. Ferguson
                                         Chief Executive Officer





                    PLEASE INDICATE YOUR VOTING INSTRUCTIONS
                           ON THE ATTACHED PROXY CARD,
                    AND SIGN, DATE AND RETURN THE PROXY CARD.
                    TO SAVE THE COST OF FURTHER SOLICITATION,
                              PLEASE VOTE PROMPTLY.



                                       3
<PAGE>

                              ADVANTEGO CORPORATION
                             1 Park Plaza, Suite 600
                                Irvine, CA 92614
                                 (949) 627-8977

                                 PROXY STATEMENT

     The accompanying  proxy is solicited by the Company's  directors for voting
at the special  meeting of  shareholders  to be held on December 12, 2019 and at
all adjournments of such meeting. If the proxy is executed and returned, it will
be  voted  at  the  meeting  in  accordance  with  any  instructions,  and if no
specification is made, the proxy will be voted for the proposal set forth in the
accompanying  notice of the special meeting of  shareholders.  Shareholders  who
execute  proxies may revoke  them at any time  before they are voted,  either by
writing to the  Company at the  address  shown above or in person at the time of
the meeting.  Additionally,  any later dated proxy will revoke a previous  proxy
from the same  shareholder.  This proxy  statement  was posted on the  Company's
website on or about November 1, 2019.

     As of October 30, 2019, the Company had:

     o    77,025,875  outstanding shares of common stock, with each common share
          entitled to one vote at the special meeting,

     o    100,000  outstanding  shares of Series A  preferred  stock,  with each
          share entitled to 1,000 votes at the special meeting, and

     o    240,000 outstanding shares of Series B preferred stock with each share
          entitled to one vote at the special meeting.

     Provided a quorum  consisting of a majority of the shares  entitled to vote
is present at the  meeting,  the  adoption of the  proposals  to come before the
meeting will be approved if the votes cast in favor of the  proposal  exceed the
votes cast against the proposal.

     Shares of the  Company's  common  stock  represented  by properly  executed
proxies  that  reflect  abstentions  or  "broker  non-votes"  will be counted as
present for  purposes  of  determining  the  presence of a quorum at the special
meeting.  "Broker  non-votes"  represent  shares  held  by  brokerage  firms  in
"street-name"  with  respect to which the broker has not  received  instructions
from the customer or otherwise  does not have  discretionary  voting  authority.
Abstentions and broker non-votes will not be counted as having voted against the
proposal to be considered at the meeting.

PRINCIPAL SHAREHOLDERS

     The following table lists, as of October 30, 2019, the shareholdings of (i)
each person owning  beneficially 5% or more of the Company's common stock;  (ii)
each executive  officer and director of the Company,  and (iii) all officers and
directors as a group. Unless otherwise indicated, each owner has sole voting and
investment power over his shares of common stock.


                                       4
<PAGE>

<TABLE>
<S>               <C>                                          <C>                                 <C>

         Name and Address                              Number of Shares                      Percent of Class

         Robert W. Ferguson                                    4,576,454                              5.9%
         1 Park Plaza, Suite 600
         Irvine, CA 92614

         Fred Popke                                            4,651,454                              6.0%
         1 Park Plaza, Suite 600
         Irvine, CA 92614

         Tracy A. Madsen                                          64,795                               NIL
         17 N. Foxhill Rd.
         North Salt Lake, UT 84054

         John J. Carvelli                                             --                                --
         450 Vista Roma
         Newport Beach, CA  92660

         James Mason                                                  --                                --
         1 Park Plaza, Suite 600
         Irvine, CA 92614

         All Officers and Directors                            9,292,703                               12%
         as a group (5 persons)

</TABLE>

     The following  table lists,  as of October 30, 2019, the  shareholdings  of
each person  owning the Company's  Series A preferred  stock.  Unless  otherwise
indicated,  each owner has sole voting and  investment  power over his shares of
preferred stock:

<TABLE>
<S>             <C>                                           <C>                                  <C>

         Name and Address                              Number of Shares (1)                  Percent of Class
         ----------------                              ----------------                      ----------------

         Robert W. Feguson                                        50,000                               50%
         1 Park Plaza, Suite 600
         Irvine, CA 92614

         Fred Popke                                               50,000                               50%
         1 Park Plaza, Suite 600
         Irvine, CA 92614
</TABLE>

(1)  Each  Series  A  preferred  share  is  convertible  into  one  share of the
     Company's  common  stock  and is  entitled  to 1,000  votes  on any  matter
     submitted to the Company's shareholders.

     The following  table lists,  as of October 30, 2019, the  shareholdings  of
each person  owning the Company's  Series B preferred  stock.  Unless  otherwise
indicated,  each owner has sole voting and  investment  power over his shares of
preferred stock:

                                       5
<PAGE>

<TABLE>
<S>            <C>                                            <C>                                   <C>

         Name and Address                              Number of Shares (1)                  Percent of Class
         ----------------                              ----------------                      ----------------

         Steve Olson                                              30,000                               13%
         30-4 Woodland Hills Drive
         Southgate, Kentucky 41071

         Joseph Smith                                             25,000                               10%
         725 College Terrace
         Niagara Falls, NY 14305

         Stuart Rubin                                             25,000                               10%
         5876 N.W. 54th Circle
         Coral Springs, FL 33067

         Robert W. Feguson                                        80,000                               33%
         1 Park Plaza, Suite 600
         Irvine, CA 92614

         Fred Popke                                               80,000                               33%
         1 Park Plaza, Suite 600
         Irvine, CA 92614

</TABLE>

(1)  Each Series B preferred  share is  convertible  into one-half of a share of
     the  Company's  common  stock  and is  entitled  to one vote on any  matter
     submitted to the Company's shareholders.

PROPOSAL TO INCREASE THE AUTHORIZED COMMON STOCK OF THE COMPANY

     Currently,  the  Company is  authorized  to issue  2,000,000,000  shares of
Common Stock. As of the October 30, 2019 there were 77,025,875  shares of Common
Stock outstanding,  with  approximately  10,180,000 shares needed to be reserved
for the issuance upon conversion of outstanding  notes. The agreements with most
of the holders of the Company's convertible notes require the Company to reserve
with its  transfer  agent a multiple  of the  shares  which the  Company  may be
required to issue upon the  conversion of the notes.  As of October 30, 2019 the
Company was required to reserve for issuance approximately  10,180,000 shares of
common stock, even though the actual number of shares which the Company would be
required to issue as of October 30, 2019 upon the conversion of all  outstanding
notes would be approximately 2,540,000 shares of common stock.

     Consequently, the Company does not have sufficient shares to meet the share
reserve  requirements  as provided by the terms of its agreements  with the note
holders.

     As a general matter,  the Board of Directors does not believe the currently
available  number of unissued  shares of Common  Stock is an adequate  number of
shares to assure that there will be sufficient  shares available for issuance in
connection  with  possible   future   acquisitions,   equity  and   equity-based
financings,   possible  future  awards  under  employee  benefit  plans,   stock
dividends,  stock splits, and other corporate purposes.  Therefore, the Board of
Directors  has approved the increase in  authorized  shares of Common Stock as a

                                       6
<PAGE>

means of providing the Company with the  flexibility  to act with respect to the
issuance  of  either  the  Common  Stock  or  securities   exercisable  for,  or
convertible into Common Stock in  circumstances  which they believe will advance
the interests of the Company and its  stockholders  without the delay of seeking
an amendment to the Articles of Incorporation at that time.

     The Company currently does not have sufficient funds to fund operations and
pay its debt obligations as they become due. As a result, the Board of Directors
is  considering,  and will  continue to  consider,  various  financing  options,
including  the issuance of Common Stock or  securities  convertible  into Common
Stock from time to time to raise  additional  capital  necessary  to support the
future growth of the Company. As a result of the increase in authorized capital,
the Board of Directors  will have more  flexibility to pursue  opportunities  to
engage in possible future capital market transactions  involving Common Stock or
other securities convertible into Common Stock,  including,  without limitation,
public  offerings  or private  placements  of such  Common  Stock or  securities
convertible  into Common Stock.  With the increase to  15,000,000,000  shares of
authorized  Common Stock the Company could raise  substantial  funds through the
issuance  of  convertible  debt  to  help  fund  operations  and  pay  its  debt
obligations.   The  issuance  of  such  convertible  notes  and  the  subsequent
conversion  by those  noteholders  could cause the Company to issue  substantial
shares of its Common Stock, causing dilution to existing shareholders.

     The additional  shares of Common Stock which may be authorized for issuance
may be issued for any proper purpose from time to time upon authorization by the
Board of Directors, without further approval by the stockholders unless required
by applicable law, rule or regulation,  including,  without limitation, rules of
any trading  market that the  Company's  Common Stock may trade on at that time.
Shares  may be  issued  for such  consideration  as the Board of  Directors  may
determine and as may be permitted by applicable law.

     The increase in the authorized shares of Common Stock is not intended to be
as a means of  preventing  or  dissuading a change in control or takeover of the
Company. However, use of these shares for such a purpose is possible. Authorized
but unissued or unreserved shares of Common Stock, for example,  could be issued
in an effort to dilute the stock  ownership and voting power of persons  seeking
to obtain  control  of the  Company or could be issued to  purchasers  who would
support the Board of Directors in opposing a takeover proposal. In addition, the
increase  in  authorized   shares  of  Common  Stock  may  have  the  effect  of
discouraging  a  challenge  for  control  or  make it less  likely  that  such a
challenge,  if  attempted,  would be  successful.  The  Board of  Directors  and
executive  officers of the Company have no  knowledge  of any current  effort to
obtain control of the Company or to accumulate large amounts of Common Stock.

     The  holders of Common  Stock are not  entitled to  preemptive  rights with
respect to the issuance of  additional  Common Stock or  securities  convertible
into or exercisable for Common Stock.

     The  holders  of  Common  Stock  will not  realize  any  dilution  in their
percentage of ownership of our company or their voting rights as a result of the
increase.  However,  issuances of  significant  numbers of additional  shares of
Common Stock in the future (i) will dilute stockholders' percentage ownership of

                                       7
<PAGE>

our  company  and (ii) if such  shares are issued at prices  below what  current
stockholders   paid  for  their   shares,   may  dilute  the  value  of  current
stockholders' shares.

     The  increase  in  authorized  capital  will not  change  the  terms of the
Company's  outstanding  Common  Stock.  The  additional  Common  Stock for which
authorization is sought will have the same voting rights and liquidation rights,
the same rights to  dividends  and  distributions  and will be  identical in all
other respects to the Common Stock now authorized.

     The Company is presently authorized to issue 10,000,000 shares of preferred
stock,  If adopted,  the proposal to increase the number of common  shares which
the  Company is  authorized  to issue will not have any effect on the  Company's
preferred stock.

     If the proposal to increase the Company's  capitalization is approved,  the
Amendment  to the  Company's  Articles  of  Incorporation,  a copy of  which  is
attached to this proxy statement,  will be filed with the Colorado  Secretary of
State.

     No dissenters'  or appraisal  rights under Colorado law are afforded to the
Company's  stockholders  as a result  of the  approval  of the  increase  in the
authorized capital.

WHERE YOU CAN FIND MORE INFORMATION

     The Company is subject to the  informational  requirements  of the Exchange
Act and files reports and other information with the SEC. Such reports and other
information filed by the Company may be inspected and copied at the SEC's Public
Reference Room at 100 F Street, N.E., Washington,  D.C.20549,  as well as in the
SEC's public reference rooms in New York, New York and Chicago, Illinois. Please
call the SEC at 1-800-SEC-0330  for further  information on the operation of the
SEC's public  reference  rooms.  The SEC also  maintains  an Internet  site that
contains reports, proxy statements and other information about issuers, like us,
who file  electronically  with the SEC.  The  address  of the  SEC's web site is
http://www.sec.gov.

GENERAL

     The  cost  of   preparing,   printing  and  mailing  the  enclosed   proxy,
accompanying notice and proxy statement,  and all other costs in connection with
solicitation  of proxies will be paid by the Company.  Failure of a quorum to be
present at the meeting will necessitate adjournment and will subject the Company
to additional expense.

     The  Company's  Board of Directors  does not intend to present and does not
have reason to believe  that others will  present any other items of business at
the annual  meeting.  However,  if other  matters are properly  presented to the
meeting for a vote,  the proxies will be voted upon such  matters in  accordance
with the judgment of the persons acting under the proxies.

                                       8
<PAGE>


                              ADVANTEGO CORPORATION
               NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS

     Important  Notice  Regarding the  Availability  of Proxy  Materials for the
Special Shareholder's Meeting to Be Held on December 12, 2019.

     1.   This notice is not a form for voting.

     2.   This  communication  presents  only an overview  of the more  complete
          proxy  materials  that  are  available  to  you on  the  Internet.  We
          encourage  you to access and review all of the  important  information
          contained in the proxy materials before voting.

     3.   The Notice of the Special  Meeting of  Shareholders  and related Proxy
          Statement are available at www.advantego.com.

     4.   If you want to receive a paper or email copy of these  documents,  you
          must  request  one.  There is no charge to you for  requesting a copy.
          Please make your request for a copy as  instructed  below on or before
          November 15, 2019 to facilitate timely delivery.

     The special  meeting of the Company's  shareholders  will be held at 1 Park
Plaza,  , Suite 600, Large  Conference  Room,  Irvine,  CA 92614 on December 12,
2019, at 10:00 a.m. Pacific Time, for the following purposes:

                  to approve an amendment to the Company's Articles of
                  Incorporation to increase the Company's authorized
                  capitalization to 15,000,000,000 shares of common stock.

     The Board of Directors  recommends that  shareholders vote FOR the proposal
to increase the authorized shares of the Company's common stock.

       October 30, 2019 is the record date for the determination of shareholders
entitled to notice of and to vote at such meeting. Holders of the Company's
common stock and Series B preferred stock may cast one vote for each share held.

         Shareholders may access the following documents at
www.advantego.com/investor:

     o    Notice of the Special Meeting of Shareholders;
     o    Company's Proxy Statement;
     o    Proxy Card; and
     o    December 31, 2018 10-K report.

         Shareholders may request a paper copy of the Proxy Materials and Proxy
Card by calling (949) 627-8977, by emailing the Company at
shareholders@advantego.com, or by visiting

                                       9
<PAGE>

www.advantego.com/investor/#notifications and indicating if you want a paper
copy of the proxy materials and proxy card:

     o    for this meeting only; or
     o    for this meeting and all other meetings.

     If you have a stock  certificate  registered in your name, or if you have a
proxy from a  shareholder  of record on October 30,  2019,  you can, if desired,
attend  the  special  meeting  and  vote  in  person.  Shareholders  can  obtain
directions     to    the    2019     special     shareholders'     meeting    at
www.advantego.com/contact.

     Please  visit  www.advantego.com/investor  to print  and fill out the Proxy
Card. Complete and sign the proxy card and mail the Proxy Card to:


                              Advantego Corporation
                             1 Park Plaza, Suite 600
                                Irvine, CA 92614
                                 (949) 627-8977















                                       10
<PAGE>

                                      PROXY

                              ADVANTEGO CORPORATION
           This Proxy is solicited by the Company's Board of Directors

The undersigned stockholder of the Company acknowledges receipt of the Notice of
the Special  Meeting of  Stockholders  to be held on December 12, 2019, at 10:00
a.m., local time, at 1 Park Plaza,  Suite 600, Large Conference Room, Irvine, CA
92614, and hereby appoints Robert W. Ferguson with the power of substitution, as
Attorney  and Proxy to vote all the shares of the  undersigned  at said  special
meeting of stockholders  and at all adjournments  thereof,  hereby ratifying and
confirming all that said Attorney and Proxy may do or cause to be done by virtue
hereof.  The above named Attorneys and Proxies are instructed to vote all of the
undersigned's shares as follows:

(1)  to approve an amendment to the Company's Articles of Incorporation to
     increase the Company's authorized capitalization to 15,000,000,000 shares
     of common stock;

            [ ]  FOR            [ ]  AGAINST              [ ] ABSTAIN

      to transact such other business as may come before the meeting.

THIS PROXY,  WHEN  PROPERLY  EXECUTED,  WILL BE VOTED AS DIRECTED  HEREIN BY THE
UNDERSIGNED STOCKHOLDER IF NO DISCRETION IS INDICATED,  THIS PROXY WILL BE VOTED
IN FAVOR OF ITEM 1.

                                    Dated this ____ day of _____________, 2019.


                                    ---------------------------------------
                                                (Signature)

                                    ---------------------------------------
                                                (Print Name)

                 Please sign your name exactly as it appears on
                      your stock certificate. If shares are
                     held jointly, each holder should sign.
                Executors, trustees, and other fiduciaries should
             so indicate when signing. Please Sign, Date and Return
           this Proxy so that your shares may be voted at the meeting.

               Send your proxy by regular mail, email, or fax to:

                          Advantego Technologies, Inc.
                             Attn: Legal Department
                             1 Park Plaza, Suite 600
                                Irvine, CA 92614
                                 (949) 627-8977
                        Email: shareholders@advantego.com
                               Fax: (949) 272-0059











                                       11
<PAGE>

                    AMENDEDMENT TO ARTICLES OF INCORPORATION


     The aggregate number of Common Shares which the Corporation  shall have the
authority to issue is Fifteen Billion (15,000,000,000), all of one class and all
with a par value of $.0001 per share;  the aggregate  number of Preferred Shares
which  the  Corporation  shall  have  the  authority  to  issue  is Ten  Million
(10,000,000),  all with a par value of $.01 per share  and of such  classes  and
with such rights,  preferences  and  limitations as the  Corporation's  Board of
Directors may determine from time to time.
